Viloxazine

  • TRADE NAME: Qelbree (Supernus)
  • INDICATIONS: Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
  • CLASS: Norepinephrine reuptake inhibitor
  • HALF-LIFE: ~7 hours

FDA APPROVAL DATE: 04/02/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfentanil, Alosetron, Atomoxetine, Avanafil, Clozapine, Conivaptan, CYP1A2 substrates, CYP2D6 substrates, CYP3A4 substrates, Darunavir, Desipramine, Dextromethorphan, Duloxetine, Everolimus, Ibrutinib, Isocarboxazid, Lomitapide, Lovastatin, Lurasidone, Metoprolol, Midazolam, monoamine oxidase inhibitors, Naloxegol, Nebivolol, Nisoldipine, Nortriptyline, Perphenazine, Phenelzine, Pirfenidone, Ramelteon, Rasagiline, Risperidone, Safinamide, Saquinavir, Selegiline, Simvastatin, Sirolimus, Tacrolimus, Tasimelteon, Theophylline, Tipranavir, Tizanidine, Tolterodine, Tranylcypromine, Triazolam, Vardenafil, Venlafaxine


May cause maternal harm; discontinue when pregnancy is recognized.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

IN CLINICAL TRIALS, HIGHER RATES OF SUICIDAL THOUGHTS AND BEHAVIOR WERE REPORTED IN PEDIATRIC PATIENTS TREATED WITH VILOXAZINE THAN IN PATIENTS TREATED WITH PLACEBO. CLOSELY MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS.


See full prescribing information for complete boxed warning

Our database has 16 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top